Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL!!! Well that is one move I would be ok with.
Its end of the year Tax selling happens every year at this time. These plays will bounce hard soon enough. There was no reason at all for this one to dip other that than. Its exactly the reason the last week or so of the year I make no moves at all.
VBIV is getting some legs!
Just went green. I think we could see 3.60 close IMO.
I just filled my order. I moved it up. Again could it see 3.30 maybe but my gut feeling says this goes green again today and we see a close of 3.60. I guess time will tell.
VBIV I have my last buy probably of the year in right now at 3.30 lets see if they fill it.
Well be glad you have your shares. I think when this one gets approval there will be a feeding frenzy.
I think that VBIV is running out of sellers and the bigger money is making their move. You know the game take it down and take out the stop losses. We hit 3.14 out the gate and now its on a nice move up.
I hear ya!
There you go! LOL!
Telling you bro. I think ATRA is a double from here soon. This company has so many irons in the fire.
Glad I bought back into ATRA the other day at 21.60
They better hurry up. That Golden cross on the weekly is coming very soon. That will be very bullish.
I got my Boss into some back under $3 and he called me the other day and was DUDE!!! LOL!
VBIV this one is getting ready. The RSI, MACD, and FUllsto on the daily just crossed up here. The MACD on the weekly is right there about to cross up. Big move coming!
CGIX Nice run!, Had this one a long time ago but sold it to buy VBIV when it was down around .84 so no regrets! CGIX nice move could see $3 pretty easy.
Agree 100%!
No sorry I liked the story but the stock could just not move and then got killed. I have moved on.
Thanks bro!
Also I did buy back my ATRA shares yesterday. I still feel this is a $40 stock one of these days.
Watch SESN. This one looks like it can test 2.50 at any time. Any good news on their bladder cancer drug and this one goes hard. I still feel very strong they get approval to be honest with you. The data has been nice!. This is the type of drug that Produce nice revenue. Not bad for a company with very little debt.
VBIV IMO is going to see a HUGE!! break out soon. Look at the 5 year weekly chart. I think we get another trip back to $7 soon. Keep your eye on $7 Back in OCT 2017 this one hit that 6.50 7.0 range and came back down. Then in Aug of this year we tested it again and came back down. Now we have that golden cross coming on the weekly. That should be strong enough to get us through $7. If that happens this one can see a big run.
I mis spoke! Its in phase 2 a of their first trial. So its still early.
Here bro. Its early but still impressive.
VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM
November 19, 2020
Interim data show promising disease control rates in patients vaccinated with VBI-1901 combined with the GM-CSF adjuvant (40%), and with VBI-1901 combined with GSK’s adjuvant AS011 (56%)
2 partial responses observed in VBI-1901 + GM-CSF study arm, with tumor reduction of more than 50%, and 7 stable disease observations across both vaccinated groups
VBI-1901 was well-tolerated with both adjuvants – no safety signals observed in either vaccinated group
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced Phase 2a (Part B) data from its ongoing Phase 1/2a study of VBI-1901, the company’s cancer vaccine immunotherapeutic candidate designed to target cytomegalovirus (CMV) as a foreign viral antigen in recurrent glioblastoma (GBM). The data were presented in an e-poster at the Society for Neuro-Oncology (SNO) 2020 Annual Meeting, November 19-21, 2020.
Data from Phase 2a (Part B) of the ongoing study showed:
2 partial responses (PRs) and 2 stable disease (SD) observed in the VBI-1901 + GM-CSF vaccinated group, resulting in a disease control rate of 40% (n=4/10)
A 56% disease control rate achieved in the group vaccinated with VBI-1901 + AS01, with 5 stable disease observations (n=5/9) – tumor response data for the 10th patient enrolled is pending
Presumed pseudoprogression was observed in both vaccinated groups– defined as immune infiltration into the tumor which appears initially as tumor growth, but later subsides resulting in tumor growth stabilization and/or shrinkage
Download e-Poster Presentation
Andrew B. Lassman, M.D., Chief of Neuro-oncology at Columbia University Irving Medical Center and Associate Director for Clinical Trials at the Herbert Irving Comprehensive Cancer Center, and principal investigator of the study presented the e-poster, commenting, “Tumor response data is one of the most objective measures of efficacy in open label studies, especially in this difficult-to-treat patient population. Few treatment options are available to recurrent glioblastoma patients, and the tumor response data seen to-date in this ongoing study are encouraging. Any treatment that could demonstrate clinical benefit would be incredibly meaningful.”
Watch Webcast
Emmanuel Hanon, Senior Vice President, Head of R&D Vaccines at GSK, commented, “The early data seen to-date in this ongoing study are encouraging, underscoring the potential benefit of adjuvants in combination with VBI-1901 in the clinical setting. Previous research in the context of other vaccines has shown AS01’s ability to boost T cell-mediated immunity. This is the first time GSK’s adjuvant system is assessed in oncology and we are looking forward to getting more data about the potential of therapeutic vaccination to treat such an aggressive and recurring disease.”
David E. Anderson, Ph.D., VBI’s Chief Scientific Officer, commented, “This ongoing study continues to demonstrate the potential of VBI-1901, with both the GM-CSF adjuvant and GSK’s AS01 adjuvant system, to be an effective cancer vaccine immunotherapeutic. The tumor responses seen to-date across both study arms, including 2 partial responses and 7 stable disease, are meaningful, especially as an outcome of a monotherapy. This data supports the continued development of the program, both as a monotherapy as well as part of a combination regimen.”
Based on the available data, VBI is exploring a randomized, controlled clinical study, including a potential registration study, for the next phase of development, which could begin in 2021, pending approval from regulatory bodies.
A webcast of Dr. Anderson discussing these data with Jeff Baxter, VBI’s President and CEO, can be found here: https://www.vbivaccines.com/wire/vbi-1901-sno-2020-update/.
A copy of the e-poster is available on the “Events/Presentations” page in the “Investors” section of the VBI Vaccines website.
About the Phase 1/2a Study Design
VBI’s two-part Phase 1/2a study is a multi-center, open-label, dose-escalation study of VBI-1901 in up to 38 patients with recurrent GBM:
Phase 1 (Part A)
Dose-escalation phase that defined the safety, tolerability, and optimal dose level of VBI-1901 adjuvanted with granulocyte-macrophage colony-stimulating factor (GM-CSF) in recurrent GBM patients with any number of prior recurrences.
This phase enrolled 18 recurrent GBM patients across three dose cohorts of VBI-1901: 0.4 µg, 2.0 µg, and 10.0 µg.
Enrollment completed in December 2018.
Phase 2a (Part B)
Subsequent extension of the optimal dose level, 10.0 µg, as defined in the Part A dose escalation phase.
This phase is a two-arm study, enrolling 10 first-recurrent GBM patients in each vaccinated group, assessing 10.0 µg of VBI-1901 in combination with either GM-CSF or GSK’s proprietary AS01 adjuvant system as immunomodulatory adjuvants.
Enrollment of the 10 patients in each adjuvant group is complete.
VBI-1901 is administered intradermally when adjuvanted with GM-CSF and intramuscularly when adjuvanted with GSK’s AS01 adjuvant system. Patients in both phases of the study receive the vaccine immunotherapeutic every four weeks until tumor progression.
About VBI-1901 and GBM
VBI-1901 is a novel cancer vaccine immunotherapeutic candidate developed using VBI’s enveloped virus-like particle (eVLP) technology to target two highly immunogenic cytomegalovirus (CMV) antigens, gB and pp65. Scientific literature suggests CMV infection is prevalent in multiple solid tumors, including glioblastoma (GBM). GBM is among the most common and aggressive malignant primary brain tumors in humans. In the U.S. alone, 12,000 new cases are diagnosed each year. The current standard of care for treating GBM is surgical resection, followed by radiation and chemotherapy. Even with aggressive treatment, GBM progresses rapidly and has a high mortality.
Makes two of us in it for HEP B potential but their COVID drug has major potential. But remember they also have a pretty impressive cancer drug.
Been saying for a long time VBIV's ability to one dose a VAC is pretty powerful and would not shock me to see them bought out sooner or later.
Yes VBIV's chart screams big break out coming. I am locked and loaded on this one. Should get interesting soon.
Picked up another 1200 VBIV today. This one is consolidating nice here. That golden cross on the weekly is closing in nice.
VBIV is looking really good. I want to see a break of 3.50 today.
No I did not get into that one.
I see 1.72 but who's splitting hairs!! LOL!!
SESN is rocking and rolling after yesterdays backfill!
The fact that the cloud went Green is very nice to see!!!
I agree I Think VBIV can without a doubt be a $10 stock pretty easy. Their revenue should really start to grow soon. Their new Hep b Vac is best in class looking at the Data.
I do not blame you this one is ready for a much bigger move. Also did you see AG announce they will issue a dividend. Not bad at all!!
SESN looks great!! This one should touch $2 soon.
AG stated today they are starting to issue a dividend. That is pretty nice news!
VBIV is about to have a big run! Just have to have some patience and we should all be looking great!
I agree break 1.60 and we see 2+ easy.
Have not looked at it in awhile. Its on the watch list but had moved on to other plays.